Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 9982223
• 负责人: WILLIAM G HAWKINS
• 金额: $ 218.47万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-28 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9982223
• 关键词: Antineoplastic Agents; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Research Project; Cancer Vaccines; Clinic; Clinical; Clinical Sciences; Clinical Trials; Collaborations; Dendritic Cells; Development; Diagnosis; Disabled Persons; Disease; Drug Monitoring; Drug Targeting; Drug Utilization; Ensure; Environment; Ethics; Female; Fostering; Genomics; Goals; Image; Immunologics; Immunology; Immunosuppression; Immunotherapy; Individual; Infrastructure; Institution; KRAS2 gene; Ligands; Malignant neoplasm of pancreas; Mentors; Minority; Mission; Morbidity - disease rate; Myeloid-derived suppressor cells; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Radiology Specialty; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Science; Specialized Program of Research Excellence; Testing; Therapeutic; Therapeutic Clinical Trial; Therapeutic Trials; Tissues; Training; Translational Research; Translations; Universities; Washington; Work; animal imaging; anti-tumor immune response; cancer therapy; career; clinical development; clinical practice; design; drug development; improved; inhibitor/antagonist; innovation; inter-institutional; leukemia; malignant breast neoplasm; migration; mortality; mutant; novel; novel diagnostics; novel imaging technique; novel strategies; novel therapeutic intervention; novel therapeutics; patient population; preclinical study; prevent; programs; recruit; response; small molecule inhibitor; small molecule therapeutics; translational cancer research; tumor; tumor microenvironment

PROJECT SUMMARY The Washington University Pancreatic Cancer Specialized Program of Research Excellence (SPORE) is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical sciences, and our teams leverage individual expertise in immunology, drug development, genomics, and imaging to develop novel diagnostic and therapeutic approaches to PDAC. This SPORE includes four research projects, an administrative core, two shared-resources cores, and developmental research and career enhancement programs. With the help of our External and Internal Advisory Boards, we have intentionally selected the projects that have the greatest potential to impact PDAC. All four of our selected projects include a therapeutic trial, and two take advantage of immunologic discoveries made at WU. We have two projects that utilize small molecule inhibitors of pathways that are known to be active in PDAC. The four projects in our application are designed to have significant potential to change clinical practice within five years. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW V-49 Project 3: Combination Inhibition of ERK for Pancreatic Cancer Treatment Project 4: Translation and Preclinical Studies of a Personalized Pancreatic Cancer Vaccine Our long-term goal is to improve survival of patients diagnosed with PDAC. To achieve this, we will promote institutional and inter-institutional collaborative science, with an emphasis on translation. We expect that no singular approach will solve PDAC, and fully commit to supporting the development of novel ideas and young investigators. Our SPORE will provide access to pancreatic cancer-specific resources to facilitate this mission.

项目摘要 华盛顿大学胰腺癌专业卓越研究计划（SPORE）是一个 高度转化的癌症研究计划完全集中在疾病的最致命的形式，胰腺癌 导管腺癌（PDAC）。我们优秀的调查人员在基础和 临床科学，我们的团队利用免疫学，药物开发，基因组学， 和成像，以开发PDAC的新诊断和治疗方法。 该SPORE包括四个研究项目，一个管理核心，两个共享资源核心， 发展研究和职业发展计划。在我们内部和外部的帮助下， 咨询委员会，我们特意选择了最有可能影响PDAC的项目。 我们选择的四个项目都包括一个治疗试验，两个利用免疫学发现 在吴。我们有两个项目，利用小分子抑制剂的途径， 活跃在PDAC我们申请中的四个项目旨在具有改变临床 五年内实践。 项目1：克服肿瘤诱导的免疫抑制以改善对免疫治疗的反应 项目2：胰腺癌药物偶联物SW V-49的临床开发 项目3：联合抑制ERK治疗胰腺癌 项目4：个性化胰腺癌疫苗的转化和临床前研究 我们的长期目标是提高PDAC患者的生存率。为了实现这一目标，我们将促进 机构和机构间的合作科学，重点是翻译。我们预计， 奇异的方法将解决PDAC，并完全致力于支持新的想法和年轻的发展 investigators.我们的SPORE将提供胰腺癌专用资源，以促进这一使命。

项目成果

Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.

• DOI: 10.1158/1055-9965.epi-19-0781
• 发表时间: 2020-01
• 期刊: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Optimal design of longitudinal data analysis using generalized estimating equation models.

使用通用估计方程模型的纵向数据分析的最佳设计。

• DOI: 10.1002/bimj.201600107
• 发表时间: 2017-03
• 期刊: Biometrical journal. Biometrische Zeitschrift
• 作者: Liu J;Colditz GA
• 通讯作者: Colditz GA

Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer.

• DOI: 10.1093/narcan/zcad055
• 发表时间: 2023-12
• 期刊: NAR cancer
• 影响因子: 5.1

Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study.

• DOI: 10.1016/j.jamcollsurg.2017.06.006
• 发表时间: 2017-10
• 期刊: Journal of the American College of Surgeons
• 影响因子: 5.2
• 作者: Khan AS;Williams G;Woolsey C;Liu J;Fields RC;Doyle MMB;Hawkins WG;Strasberg SM
• 通讯作者: Strasberg SM

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

• DOI: 10.18632/oncotarget.27109
• 发表时间: 2019-07-30
• 期刊: Oncotarget
• 作者: Strand, Matthew S;Krasnick, Bradley A;Fields, Ryan C
• 通讯作者: Fields, Ryan C